| Literature DB >> 24311715 |
Abstract
In this issue of Blood, Abrisqueta and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL) patients after treatment with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM).Entities:
Mesh：
Year: 2013 PMID： 24311715 DOI： 10.1182/blood-2013-10-534131
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113